Table 1. Baseline clinical characteristics of study participants at V1.

Variable	Total	Normal weight at visit 1	Overweight and obesity at visit 1	P value
No. of patients (%)	127 (100)	97 (76.4)	30 (23.6)
CA (yr)	8.5±0.5	8.5±0.5	8.5±0.5	0.876
BA (yr)	10.1±0.7	10.1±0.7	10.2±0.8	0.448
BA–CA difference (yr)	1.6±0.7	1.6±0.7	1.7±0.6	0.480
Height z score for CA	1.04±0.78	1.00±0.80	1.15±0.72	0.370
Weight z score for CA	0.72±0.74	0.45±0.60	1.61±0.40	<0.001
BMI z score for CA	0.32±0.88	−0.06±0.61	1.54±0.36	<0.001
Height z score for BA	−0.60±0.72	−0.62±0.72	−0.53±0.74	0.539
Weight z score for BA	−0.39±0.85	−0.68±0.70	0.56±0.57	<0.001
BMI z score for BA	−0.10±0.88	−0.47±0.61	1.10±0.43	<0.001
Tanner stage of breasts : II/III/IV	88/36/3	66/28/3	22/8/0	0.589
Basal LH (IU/L)	0.7±1.1	0.7±1.0	0.9±1.2	0.316
Basal FSH (IU/L)	3.3±1.8	3.1±1.6	3.6±2.5	0.183
Peak LH (IU/L)	13.9±9.3	14.2±9.5	13.0±9.0	0.542
Peak FSH (IU/L)	13.5±4.8	13.8±5.0	12.5±4.1	0.220
Estradiol (pg/mL)	15.0±15.0	14.7±14.3	16.2±17.3	0.621
Dose of GnRH agonists (µg/kg)	79.6±16.8	80.8±17.1	75.7±15.7	0.148
GnRH agonist treatment duration (yr)	2.8±0.5	2.7±0.5	2.9±0.6	0.215
Follow-up duration after GnRH agonist discontinuation (yr)	0.73±0.27	0.75±0.28	0.69±0.26	0.377

Values are presented as mean±standard deviation unless otherwise indicated.

Visit 1, at the start of GnRH agonist; CA, chronological age; BA, bone age; BMI, body mass index; LH, luteinizing hormone; FSH, follicle stimulating hormone; GnRH, gonadotropin-releasing hormone.